Marsh Robyn L, Aho Celestine, Beissbarth Jemima, Bialasiewicz Seweryn, Binks Michael, Cervin Anders, Kirkham Lea-Ann S, Lemon Katherine P, Slack Mary P E, Smith-Vaughan Heidi C
Menzies School of Health Research, Charles Darwin University, Northern Territory, Australia.
Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Int J Pediatr Otorhinolaryngol. 2020 Mar;130 Suppl 1(Suppl 1):109836. doi: 10.1016/j.ijporl.2019.109836. Epub 2019 Dec 18.
To perform a comprehensive review of otitis media microbiome literature published between 1 July 2015 and 30th June 2019.
PubMed database, National Library of Medicine.
Key topics were assigned to each panel member for detailed review. Draft reviews were collated and circulated for discussion when the panel met at the 20th International Symposium on Recent Advances in Otitis Media in June 2019. The final draft was prepared with input from all panel members.
Much has been learned about the different types of bacteria (including commensals) present in the upper respiratory microbiome, but little is known about the virome and mycobiome. A small number of studies have investigated the middle ear microbiome; however, current data are often limited by small sample sizes and methodological heterogeneity between studies. Furthermore, limited reporting of sample collection methods mean that it is often difficult to determine whether bacteria detected in middle ear fluid specimens originated from the middle ear or the external auditory canal. Recent in vitro studies suggest that bacterial interactions in the nasal/nasopharyngeal microbiome may affect otitis media pathogenesis by modifying otopathogen behaviours. Impacts of environmental pressures (e.g. smoke, nutrition) and clinical interventions (e.g. vaccination, antibiotics) on the upper respiratory and middle ear microbiomes remain poorly understood as there are few data.
Advances in understanding bacterial dynamics in the upper airway microbiome are driving development of microbiota-modifying therapies to prevent or treat disease (e.g. probiotics). Further advances in otitis media microbiomics will likely require technological improvements that overcome the current limitations of OMICs technologies when applied to low volume and low biomass specimens that potentially contain high numbers of host cells. Improved laboratory models are needed to elucidate mechanistic interactions among the upper respiratory and middle ear microbiomes. Minimum reporting standards are critically needed to improve inter-study comparisons and enable future meta-analyses.
对2015年7月1日至2019年6月30日期间发表的中耳炎微生物组文献进行全面综述。
美国国立医学图书馆的PubMed数据库。
为每位小组成员分配关键主题进行详细综述。2019年6月,在第20届中耳炎最新进展国际研讨会上,小组成员碰面时,对综述草稿进行了整理并传阅以供讨论。最终草稿在所有小组成员的参与下完成。
关于上呼吸道微生物组中存在的不同类型细菌(包括共生菌),我们已经了解了很多,但对病毒组和真菌组却知之甚少。少数研究对中耳微生物组进行了调查;然而,目前的数据往往受到样本量小和研究间方法异质性的限制。此外,样本采集方法的报告有限,这意味着通常很难确定中耳液标本中检测到的细菌是来自中耳还是外耳道。最近的体外研究表明,鼻/鼻咽微生物组中的细菌相互作用可能通过改变耳病原体行为来影响中耳炎的发病机制。由于数据较少,环境压力(如烟雾、营养)和临床干预(如疫苗接种、抗生素)对上呼吸道和中耳微生物组的影响仍知之甚少。
对上呼吸道微生物组中细菌动态的理解进展推动了微生物群调节疗法的发展,以预防或治疗疾病(如益生菌)。中耳炎微生物组学的进一步进展可能需要技术改进,以克服当前组学技术在应用于可能含有大量宿主细胞的低体积和低生物量标本时的局限性。需要改进实验室模型来阐明上呼吸道和中耳微生物组之间的机制相互作用。迫切需要最低报告标准,以改善研究间的比较并实现未来的荟萃分析。